PHIBRO ANIMAL HEALTH CORP — Form 10-K
Filed August 26, 2026 · analyzed by the Periodic Agent
10-K
— Neutral
significance 28/100
What the filing says
Daniel M. Bendheim appointed CEO and President effective July 1, 2026 at $850,000 annual base salary, 50% target bonus ($425k), annual RSU grants valued at ~50% of base (~$425k), and an initial grant of 300,000 performance-vesting RSUs tied to stock price reaching $70–$100 by June 30, 2031. Counterparty: Phibro Animal Health Corporation. Employment is at-will with 180-day termination notice required; restrictive covenants (non-compete, non-solicit) run 1 year post-termination.
Why this rating
CEO compensation package is ~$3.2M annualized (salary + target bonus + annual RSU grant), roughly 0.76% of $422.6M market cap—material but routine for public company. RSU vesting depends on stock performance, creating upside/downside. No material business change disclosed; this is normal executive governance. Standard for small-cap public company.
See more from August 26, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.